Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent and Integrated Diagnostics Enter Strategic Partnership

Published: Wednesday, January 11, 2012
Last Updated: Wednesday, January 11, 2012
Bookmark and Share
The partnership will develop protein-based assays for early disease detection.

Agilent Technologies Inc. and Integrated Diagnostics have announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect diseases such as lung cancer and Alzheimer’s at their earliest stages.

Agilent manufactures a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.

Officials of both organizations see an opportunity to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on protein and peptide biomarkers of disease.

“Agilent provides an innovative and forward-looking platform and expertise to enable the development and deployment of next-generation multiplexed proteomic assays,” said Paul Kearney, Ph.D., president and chief scientific officer, Integrated Diagnostics.

Kearney continued, “Integrated Diagnostics will bring expertise in assay development, technology strategy, study design, clinical development, commercialization and systems informatics to leverage the Agilent technology solution. Together, we intend to realize the potential of clinical proteomics today as well as establish the technological platform and strategy for the field. Our partnership with Agilent will allow us to realize the advantages of using a single technology platform from discovery and verification through to commercialization.”

“Agilent and Integrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving some of mankind’s most vexing health challenges,” said Gustavo Salem, vice president and general manager of the Biological Systems Division at Agilent.

Salem continued, “It’s very exciting to be at the forefront of helping technology migrate from the research lab to the clinic, in this case developing next-generation workflows to improve protein-based LC/MS assays.”

As part of the partnership, Integrated Diagnostics purchased two Agilent 1290 Infinity UHPLC systems, two 6490 iFunnel triple quadrupole mass spectrometry systems and two 1260 LCs with ultraviolet detectors for the project.

The partnership will develop high-throughput automated workflows to include sample preparation and LC MS/MS analysis. Participants expect accelerated biomarker discovery to be fueled by novel sample-prep technology, fast liquid chromatography and ultra-sensitive ion funnel triple quadrupole mass spectrometry.

The technology opens the possibility of screening for several hundred biomarkers in a single assay, in a very high-throughput and quantitative fashion, according to Agilent.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies Reports Second-Quarter 2012 Results
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.
Wednesday, May 16, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies and A*STAR’s ETC Launch All-in-One Drug-Screening Platform at Singapore Screening Centre
Agilent to provide a full spectrum of automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.
Tuesday, August 02, 2011
Agilent Acquires BIOCIUS Life Sciences
Agilent Technologies Inc. announces that it has acquired BIOCIUS Life Sciences, Inc., developer of the unique RapidFire™ high-throughput mass spectrometry drug-screening platform for the pharmaceutical and biopharmaceutical markets.
Thursday, March 03, 2011
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!